Search research articles
Contact Us
Filters
Showing results (71-80 of 277) with videos related to
Page
of 28
Sort By:
JTO Clinical and Research Reports
|
January 30, 2024
Novel <i>BRD2::NUTM1</i> Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report
Sarah J Wu, Justin J Kim, Yeying Huang, et al.
Cancer
|
June 19, 2026
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib
Rana R McKay, Wanling Xie, Archana Ajmera, et al.
Cell Reports
|
March 3, 2021
MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity
Timothy B Branigan, David Kozono, Amy E Schade, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 6, 2014
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors
Pasi A Jänne, Roger B Cohen, A Douglas Laird, et al.
The Journal of Experimental Medicine
|
January 23, 2023
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
Lestat R Ali, Ana C Garrido-Castro, Patrick J Lenehan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2010
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors
Richard Quek, Qian Wang, Jeffrey A Morgan, et al.
Cancer Research
|
May 4, 2012
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET
Lu Xu, Eiki Kikuchi, Chunxiao Xu, et al.
Expert Review of Anticancer Therapy
|
June 28, 2021
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
Komal Jhaveri, Howard A Burris Rd, Timothy A Yap, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 22, 2011
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer
Lee M Krug, Jeffrey Crawford, David S Ettinger, et al.
Cancer Immunology, Immunotherapy : CII
|
January 13, 2015
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)
Mario E Lacouture, John C Morris, Donald P Lawrence, et al.
Page
of 28
Search research articles
Search
Showing results (71-80 of 277) with videos related to
Sort By:
Page
of 28
JTO Clinical and Research Reports
|
January 30, 2024
Novel <i>BRD2::NUTM1</i> Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report
Sarah J Wu, Justin J Kim, Yeying Huang, et al.
Cancer
|
June 19, 2026
Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib
Rana R McKay, Wanling Xie, Archana Ajmera, et al.
Cell Reports
|
March 3, 2021
MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity
Timothy B Branigan, David Kozono, Amy E Schade, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 6, 2014
Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors
Pasi A Jänne, Roger B Cohen, A Douglas Laird, et al.
The Journal of Experimental Medicine
|
January 23, 2023
PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer
Lestat R Ali, Ana C Garrido-Castro, Patrick J Lenehan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 24, 2010
Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors
Richard Quek, Qian Wang, Jeffrey A Morgan, et al.
Cancer Research
|
May 4, 2012
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET
Lu Xu, Eiki Kikuchi, Chunxiao Xu, et al.
Expert Review of Anticancer Therapy
|
June 28, 2021
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
Komal Jhaveri, Howard A Burris Rd, Timothy A Yap, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 22, 2011
Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer
Lee M Krug, Jeffrey Crawford, David S Ettinger, et al.
Cancer Immunology, Immunotherapy : CII
|
January 13, 2015
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor β by the monoclonal antibody fresolimumab (GC1008)
Mario E Lacouture, John C Morris, Donald P Lawrence, et al.
Page
of 28